Unlocking the Potential of CD33: Targeted Solutions for Hematological Malignancies

In the landscape of cancer immunotherapy, CD33 (Siglec-3) is a well-established target and has emerged as a pivotal target for treating acute myeloid leukemia (AML) and exploring novel therapeutic avenues in neurodegenerative diseases. At RGBiotech, we provide researchers with the essential tools to explore this promising pathway. Our advanced, ready-to-use CD33 and CD33 Chimeric Antigen Receptor (CAR) expression vectors are engineered to empower researchers in unlocking the full potential of this critical target, accelerating the development of life-changing therapies.

About CD33: A Key Target in Immunotherapy

CD33, also known as Siglec-3, is a 67 kDa transmembrane glycoprotein belonging to the sialic acid-binding immunoglobulin-like lectin (Siglec) family. Characterized by an extracellular domain with two Ig-like structures (V and C2 regions) and an intracellular domain containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs), CD33 plays a crucial role in regulating myeloid cell signaling. Notably, CD33 exhibits multiple splice variants, with the CD33 ΔE2 isoform (lacking the V domain) showing distinct functional properties that have significant implications for therapeutic development.

CD33 displays a highly relevant expression pattern for targeted therapy: it is overexpressed on >90% of AML blasts and leukemia-initiating cells, while being absent from hematopoietic stem cells and only weakly expressed on mature granulocytes and circulating macrophages. This restricted expression profile makes it an ideal target for AML treatment, minimizing off-target effects on healthy hematopoietic tissue. Additionally, CD33 is expressed on microglial cells in the central nervous system, linking it to Alzheimer's disease (AD) pathogenesis.

As an inhibitory receptor, CD33 regulates myeloid cell differentiation, adhesion, and apoptosis through ITIM-mediated signaling cascades. Recent studies have identified CD45 as a key binding partner of CD33, with their interaction inhibiting CD45 phosphatase activity and impairing microglial clearance of amyloid-beta in AD models. In AML, CD33-mediated signaling contributes to immune evasion by suppressing anti-tumor T cell responses.

CD33 & Human Diseases

About CD33 CAR: Revolutionizing AML Immunotherapy

The high and specific expression of CD33 on AML blasts, while being absent on critical HSCs, makes it an ideal immunological target. Because of this, CD33 has been one of the most intensively studied targets for AML therapy. Chimeric Antigen Receptor T-cell therapy redirects a patient's own T-cells to recognize and eliminate CD33-expressing cancer cells. This approach has the potential to overcome the limitations of conventional chemotherapy.

A Chimeric Antigen Receptor (CAR) targeting CD33 is a synthetic receptor engineered to redirect T cells or natural killer (NK) cells to specifically recognize and eliminate CD33+ cancer cells. The CD33 CAR typically consists of an anti-CD33 single-chain variable fragment (scFv), a transmembrane domain, and intracellular co-stimulatory and signaling domains (e.g., CD28/4-1BB and CD3ζ), enabling potent antigen-specific cytotoxicity.

CD33 CAR-T therapy has demonstrated promising efficacy in preclinical and clinical studies: In 2019, CD33 CAR-T successfully treated a child with refractory AML, marking the second global case of such a breakthrough. Dual-target CAR-T therapies (e.g., CLL1×CD33) are currently in clinical trials, addressing the challenge of antigen loss and improving treatment durability. Novel CAR designs incorporating improved scFvs that recognize multiple CD33 isoforms are being developed to overcome resistance mediated by the CD33 ΔE2 variant.

Prospects & Challenges

While no CD33 CAR-T therapy is yet commercially approved, multiple early-phase clinical trials have demonstrated promising antileukemic activity. Research has shown that CD33 CAR-T cells can effectively induce remission in relapsed/refractory AML patients. With AML remaining a high-unmet-need disease, CD33 CAR therapies offer a personalized approach for relapsed/refractory patients. Beyond AML, CD33 targeting holds potential in AD and other myeloid-mediated disorders. Combination strategies with chemotherapy or checkpoint inhibitors are expected to further enhance efficacy.

However, the field is actively addressing key challenges. For example, 1) Since CD33 is expressed on normal myeloid cells, CAR-T therapy can lead to prolonged myelosuppression (myeloablation). This is the most significant hurdle (On-Target, Off-Tumor Toxicity). 2) The immunosuppressive bone marrow tumor microenvironment (TME) in acute myeloid leukemia (AML) can inhibit the function and persistence of chimeric antigen receptor T (CAR-T) cells. 3) Leukemia cells with low or no CD33 expression can emerge (e.g., CD33 ΔE2), leading to relapse (Antigen Escape).

The future of CD33 CAR-T therapy lies in innovative strategies to enhance safety and efficacy:
1) Safety Switches: Incorporating inducible caspase-9 (iCasp9) or other "suicide genes" to eliminate CAR-T cells if toxicity occurs.
2) Tandem or Bicistronic CARs: Targeting CD33 along with another AML-associated antigen (e.g., CLL-1 or FLT3) to prevent antigen escape.
3) Gene Editing: Using CRISPR/Cas9 to knock out the CD33 gene in hematopoietic stem cells prior to transplant, creating a "shielded" graft that is resistant to CD33 CAR-T mediated toxicity.
4) Armored CARs: Engineering CAR-T cells to secrete cytokines (e.g., IL-7, IL-15) to resist TME suppression and enhance persistence.

Empower Your Research with Our CD33 & CD33 CAR Expression Vectors

To accelerate the development of these innovative solutions, RGBiotech offers a robust and reliable CD33 and CD33 CAR Expression Plasmid Vectors, designed to accelerate your research, preclinical development and mechanistic studies. Our CD33 CAR expression vectors are developed by a team of immunologists and vector engineers with deep expertise in hematological oncology. These plasmid vectors can be delivered into target cells to create stable cell lines expressing CD33 antigen or CD33 CAR.

Highlights

Applications

Contact us at admin@rgbiotech.com today for more information, a detailed datasheet, or to discuss your specific project needs.

Disclaimer: This product is for research use only (RUO). Not for use in diagnostic or therapeutic procedures.

Contact Us